|
|
Volumn 28, Issue 11, 2010, Pages 1135-1136
|
|
Novartis eyes oral MS drug as potential blockbuster
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
BETA1A INTERFERON;
DACLIZUMAB;
FINGOLIMOD;
FIRATEGRAST;
GILENYA;
NATALIZUMAB;
OCRELIZUMAB;
UNCLASSIFIED DRUG;
BLOOD BRAIN BARRIER;
BRAIN ATROPHY;
BREATHING DISORDER;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
DRUG APPROVAL;
DRUG MARKETING;
DRUG SAFETY;
DRUG TOLERABILITY;
FOOD AND DRUG ADMINISTRATION;
HEALTH SURVEY;
HEART RATE;
HUMAN;
LIVER DISEASE;
LYMPH NODE;
LYMPHOCYTE;
MULTIPLE SCLEROSIS;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT MONITORING;
PRIORITY JOURNAL;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
RETINA MACULA EDEMA;
ADMINISTRATION, ORAL;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
LYMPHOCYTES;
LYSOPHOSPHOLIPIDS;
MULTIPLE SCLEROSIS;
PROPYLENE GLYCOLS;
SPHINGOSINE;
|
|
EID: 78149293229
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1110-1135 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
